ClinicalTrials.gg

Program

navepegritide

Also written as “Navepegritide”, “TransCon CNP” and “Dual therapy with navepegritide and lonapegsomatropin”.

Its studies are mostly in Achondroplasia, led by 3 companies.

Furthest: phase 3, since Oct 30, 20268 company-led studies, 5 open or runningNext primary completion: Sep 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ascendis Pharma54 open or runningphase 3since Oct 30, 2026Sep 9, 2019Sep 2027phase 2 · NCT06732895
Ascendis Pharma Growth Disorders21 open or runningphase 3since Oct 25, 2022Oct 25, 2022Jan 2039phase 3 · NCT05929807
Visen Pharmaceuticals (Shanghai)10 open or runningphase 2since Feb 9, 2022Feb 9, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 9, 2019First study: phase 2 study in AchondroplasiaNew to Ascendis PharmaAscendis Pharma · NCT04085523 · 57 enrolled · United States, Australia, Austria and more
  2. Feb 9, 2022Visen Pharmaceuticals (Shanghai)'s first study: phase 2 study in AchondroplasiaNew to Visen Pharmaceuticals (Shanghai)Visen Pharmaceuticals (Shanghai) · NCT05246033 · 24 enrolled · China
  3. Oct 25, 2022Ascendis Pharma Growth Disorders's first study: phase 3 study in AchondroplasiaNew to Ascendis Pharma Growth DisordersAscendis Pharma Growth Disorders · NCT05598320 · 84 enrolled · United States, Australia, Canada and more
  4. Jun 6, 2023Phase 3 study in AchondroplasiaAscendis Pharma Growth Disorders · NCT05929807 · 140 planned · United States, Australia, Austria and more
  5. Oct 6, 2023Phase 2 study in AchondroplasiaAscendis Pharma · NCT06079398 · 72 planned · United States, Australia, Austria and more
  6. Dec 10, 2024Phase 2 study in AchondroplasiaAscendis Pharma · NCT06732895 · 25 enrolled · Canada, Denmark, France and more
  7. Oct 30, 20262 phase 3 studiesPhase 3 reachedAscendis Pharma · NCT07924059, NCT07917143

Ahead

  1. Sep 2027Primary completion: phase 2 study in AchondroplasiaAscendis Pharma · NCT06732895
  2. Dec 2027Primary completion: phase 2 study in AchondroplasiaAscendis Pharma · NCT06079398
  3. Sep 2028Primary completion: phase 3 study in AchondroplasiaAscendis Pharma · NCT07924059
  4. Oct 2028Primary completion: phase 3 study in HypochondroplasiaAscendis Pharma · NCT07917143

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07924059Achondroplasia3Not yet recruitingAscendis PharmaSep 2028144
NCT07917143Hypochondroplasia3Not yet recruitingAscendis PharmaOct 202881
NCT06732895Achondroplasia · Canada, Denmark, France and more2Active, not recruitingAscendis PharmaSep 202725
NCT06079398Achondroplasia · United States, Australia, Austria and more2RecruitingAscendis PharmaDec 202772
NCT05929807Achondroplasia · United States, Australia, Austria and more3By invitationAscendis Pharma Growth DisordersJan 2039140
NCT05598320Achondroplasia · United States, Australia, Canada and more3CompletedAscendis Pharma Growth DisordersAug 9, 202484
NCT05246033Achondroplasia · China2CompletedVisen Pharmaceuticals (Shanghai)Mar 15, 202324
NCT04085523Achondroplasia · United States, Australia, Austria and more2CompletedAscendis PharmaSep 27, 202257

How it is read

Names in the registry

  • “Navepegritide”, 3 entries
  • “TransCon CNP”, 3 entries
  • “Dual therapy with navepegritide and lonapegsomatropin”, 1 entry
  • “Navepegritide (TransCon CNP)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.